Therefore, OVs already encoding tumor antigens such as the clinical candidates Ad-MAGEA3 and MRB-MAGEA3 or Ad-E6/E7 and MRB-E6/E7 could easily be used as vaccination adjuvants to target additional Muts in MAGEA3- or E6/E7-positive tumors, respectively. Here, ROBO4 is linked to neoplasm.